McGovern Susan L, Shoichet Brian K
Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, 303 East Chicago Avenue, Chicago, Illinois 60611, USA.
J Med Chem. 2003 Jul 3;46(14):2895-907. doi: 10.1021/jm0300330.
Molecular docking uses the three-dimensional structure of a receptor to screen a small molecule database for potential ligands. The dependence of docking screens on the conformation of the binding site remains an open question. To evaluate the information loss that occurs as the active site conformation becomes less defined, a small molecule database was docked against the holo (ligand bound), apo, and homology modeled structures of 10 different enzyme binding sites. The holo and apo representations were crystallographic structures taken from the Protein Data Bank (PDB), and the homology-modeled structures were taken from the publicly available resource ModBase. The database docked was the MDL Drug Data Report (MDDR), a functionally annotated database of 95000 small molecules that contained at least 35 ligands for each of the 10 systems. In all sites, at least 99% of the molecules in the MDDR were treated as nonbinding decoys. For each system, the holo, apo, and modeled structures were used to screen the MDDR, and the ability of each structure to enrich the known ligands for that system over random selection was evaluated. The best overall enrichment was produced by the holo structure in seven systems, the apo structure in two systems, and the modeled structure in one system. These results suggest that the performance of the docking calculation is affected by the particular representation of the receptor used in the screen, and that the holo structure is the one most likely to yield the best discrimination between known ligands and decoy molecules, but important exceptions to this rule also emerge from this study. Although each of the holo, apo, and modeled conformations led to enrichment of known ligands in all systems, the enrichment did not always rise to a level judged to be sufficient to justify the effort of a docking screen. Using a 20-fold enrichment of known ligands over random selection as a rough guideline for what might be enough to justify a docking screen, the holo conformation of the enzyme met this criterion in eight of 10 sites, whereas the apo conformation met this criterion in only two sites and the modeled conformation in three.
分子对接利用受体的三维结构来筛选小分子数据库以寻找潜在配体。对接筛选对结合位点构象的依赖性仍是一个悬而未决的问题。为了评估随着活性位点构象变得不那么明确而发生的信息损失,将一个小分子数据库与10个不同酶结合位点的全酶(结合配体)、脱辅基蛋白和同源建模结构进行对接。全酶和脱辅基蛋白的结构是从蛋白质数据库(PDB)获取的晶体结构,同源建模结构则取自公开可用的资源ModBase。所对接的数据库是MDL药物数据报告(MDDR),这是一个功能注释的数据库,包含95000个小分子,其中每个10个系统至少有35个配体。在所有位点,MDDR中至少99%的分子被视为非结合诱饵。对于每个系统,使用全酶、脱辅基蛋白和建模结构来筛选MDDR,并评估每种结构相对于随机选择而言富集该系统已知配体的能力。七个系统中全酶结构产生了最佳的总体富集效果,两个系统中脱辅基蛋白结构产生了最佳效果,一个系统中建模结构产生了最佳效果。这些结果表明,对接计算的性能受筛选中使用的受体的特定表示形式影响,并且全酶结构最有可能在已知配体和诱饵分子之间产生最佳区分,但该研究也出现了这条规则的重要例外情况。尽管全酶、脱辅基蛋白和建模构象在所有系统中都导致了已知配体的富集,但这种富集并不总是达到被认为足以证明对接筛选努力合理的水平。以已知配体相对于随机选择有20倍的富集作为可能足以证明对接筛选合理的大致指导标准,该酶的全酶构象在10个位点中的8个满足此标准,而脱辅基蛋白构象仅在2个位点满足此标准,建模构象在3个位点满足此标准。